Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 123

Sort by

Sort Order Select

Journal Articles

Pre-clinical efficacy of FLT3/BRAF targeting with novel dual inhibitor PHI3 in FLT3/RAS co-mutated AML

Shikhar Sharma, Anna Skwarska, Evangelia Matenoglou, Sovira Chaudhry, Murugan Selvam, Catherine Smith, Pamela Sung, Eunice Wang, Donald Small, Evripidis Gavathiotis, Marina Konopleva

Blood (2025) 146 (Supplement 1): 5062.

https://doi.org/10.1182/blood-2025-5062

Published: 2025

Journal Articles

Spatial asymmetry of blasts in bone marrow after hematopoietic stem cell transplantation for AML/MDS

Ruowen Wei, Ao Zhang, Moran Wang, Ruiqi Zhu, Donald Small, Xie-Na Cao, Yanmin Zhao, Linghui Xia, Wei Shi

Blood (2025) 146 (Supplement 1): 6040.

https://doi.org/10.1182/blood-2025-6040

Published: 2025

Journal Articles

Sphingosine-1-phosphate receptor modulators overcome FLT3 inhibitor resistance in Acute Myeloid Leukemia with FLT3-ITD and NRAS mutations through sphingosine kinase 1/AKT pathway downregulation.

Aditi Chatterjee, Moaath Mustafa Ali, Christopher Bailey, Yuchen Liu, Donald Small, Catherine Smith, Elie Traer, Yin Wang, Giovannino Silvestri, Maria Baer

Blood (2025) 146 (Supplement 1): 3288.

https://doi.org/10.1182/blood-2025-3288

Published: 2025

Journal Articles

PHI-101, a Novel FLT3 TKI, Shows Clinical Efficacy in Relapsed/Refractory FLT3-Mutated AML

Blood (2024) 144 (Supplement 1): 1495.

https://doi.org/10.1182/blood-2024-207033

Published: 2024

Journal Articles

Evaluation of Synergistic Anti-Leukemic Efficacy of PHI-101 in Preclinical Model of FLT3-ITD Acute Myeloid Leukemia

Gi-Jun Sung, Kyung-Ah Kim, Ky-Youb Nam, Kyu-Tae Kim, June Han, JeongHyeok Yoon, Li Li, Bao Nguyen, Tessa Seale, Donald Small

Blood (2023) 142 (Supplement 1): 5949.

https://doi.org/10.1182/blood-2023-185759

Published: 2023

Journal Articles

Long Noncoding RNA NEAT1 Regulates Acute Graft-Versus-Host Disease By Promoting Macrophage M1 Polarization through JNK Pathway

Ran Zhang, Zhenli Huang, Li Wang, Weijie Cao, Donald Small, Ruiqi Zhu, Wei Shi, Zhongxing Jiang, Linghui Xia

Blood (2023) 142 (Supplement 1): 2053.

https://doi.org/10.1182/blood-2023-189758

Published: 2023

Journal Articles

PHI-101 As a Potent Next-Generation FLT3 Inhibitor, Overcome Resistances in Previously Treated Patients with FLT3-ITD or TKD Acute Myeloid Leukemia: Results of a Phase Ia/Ib Clinical Trial

Sung-Soo Yoon, Dongyeop Shin, Je-Hwan Lee, Jun Ho Jang, June-Won Cheong, Ho-Jin Shin, Jeong-Ok Lee, Yoo Jin Lee, Joseph Clarey, Gi-Jun Sung, Kyung-Ah Kim, Ky-Youb Nam, Kyu-Tae Kim, June Han, JeongHyeok Yoon, Bao Nguyen, Li Li, Donald Small

Blood (2023) 142 (Supplement 1): 4283.

https://doi.org/10.1182/blood-2023-185606

Published: 2023

Journal Articles

SHP2 Inhibition Overcomes Adaptive and Acquired Resistance to FLT3 TKI to Improve Efficacy Against FLT3/ITD AML

Tessa Seale, Li Li, J. Kyle Bruner, Bao Nguyen, Mark J. Levis, Christine Pratilas, Donald Small

Blood (2023) 142 (Supplement 1): 2790.

https://doi.org/10.1182/blood-2023-184338

Published: 2023

Journal Articles

Targeting SIRT5 By Succinylating Hadha Synergizes with Venetoclax in Acute Myeloid Leukemia

Moran Wang, Wei Shi, Ruiqi Zhu, Donald Small, Li Li, Shengling Ma, Yu Hu

Blood (2023) 142 (Supplement 1): 4164.

https://doi.org/10.1182/blood-2023-178420

Published: 2023

Journal Articles

Inhibition of NOTCH4 Sensitizes FLT3/ITD Acute Myeloid Leukemia Cells to FLT3 Tyrosine Kinase Inhibition

Ruiqi Zhu, Courtney Shirley, Haihua Chu, Li Li, Bao Nguyen, Jaesung Seo, Tessa Seale, Amy Duffield, Louis M. Staudt, Mark J. Levis, Yu Hu, Donald Small

Blood (2023) 142 (Supplement 1): 5769.

https://doi.org/10.1182/blood-2023-190696

Published: 2023

Journal Articles

Humanized Anti-CD25 Monoclonal Antibody Replacing MTX for Graft-Versus-Host Disease Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplantation

Zhenli Huang, Ran Zhang, Donald Small, Ruiqi Zhu, Wei Shi, Linghui Xia

Blood (2023) 142 (Supplement 1): 4913.

https://doi.org/10.1182/blood-2023-186247

Published: 2023

Journal Articles

A Potent Small Molecule Inhibitor of FLT3, PHI-101 Overcomes Resistance in Acute Myeloid Leukemia: Efficacy and PK/PD Profile in Phase 1 First in Human Study

Sung-Soo Yoon, Dong-Yeop Shin, Je-Hwan Lee, Jun Ho Jang, June-Won Cheong, Ho-Jin Shin, Jeong-Ok Lee, Yunsuk Choi, Joseph Clarey, Jeejin Im, Suntae Kim, Ky-Youb Nam, Kyu-Tae Kim, June Han, Jeong Hyeok Yoon, Bao Nguyen, Li Li, Donald Small

Blood (2022) 140 (Supplement 1): 3365–3366.

https://doi.org/10.1182/blood-2022-165000

Published: 2022

Journal Articles

A Phase 1a/1b First in Human Study of PHI-101, a Potent Small Molecule Inhibitor of FLT3 in Relapsed and Refractory Acute Myeloid Leukemia

Sung-Soo Yoon, Dong-Yeop Shin, Je-Hwan Lee, Jun Ho Jang, June-Won Cheong, Ho-Jin Shin, Jeong-Ok Lee, Yunsuk Choi, Anish Puliyayil, Joseph Clarey, Jeejin Im, Ky-Youb Nam, Kyu-Tae Kim, June H-J. Han, Jeong-Hyeok Yoon, Bao Nguyen, Li Li, Donald Small

Blood (2021) 138 (Supplement 1): 3425.

https://doi.org/10.1182/blood-2021-149395

Published: 2021

Journal Articles

PHI-101 Is a Potent Third-Generation FLT3 Inhibitor Developed to Overcome Resistance in Acute Myeloid Leukemia

Ky-Youb Nam, PhD, Jeejin Im, June H-J H-J Han, Kyu-Tae Kim, PhD, Jeong-Hyeok Yoon, PhD, Hanna Cho, PhD, Seung-Hye Choi, PhD, David Young, MD, Bao Nguyen, Ruiqi Zhu, PhD, Li Li, MD,PhD, Donald Small, MD, PhD, Taebo Sim, PhD

Blood (2020) 136 (Supplement 1): 28.

https://doi.org/10.1182/blood-2020-139044

Published: 2020

Journal Articles

Dissociation of the DNMT3A-HDAC1 Repressor Complex Induces PD-L1 Expression

Jaesung Seo, PhD, Li Li, MD PhD, Donald Small, MD PhD

Blood (2019) 134 (Supplement_1): 3759.

https://doi.org/10.1182/blood-2019-130339

Published: 2019

Journal Articles

DOCK2 Expression Affects Leukemogenesis and Disease Progression in a Murine Model of FLT3/ITD Acute Myeloid Leukemia

Min Wu, PhD, Li Li, MD PhD, Donald Small, MD PhD, Amy S. Duffield, MD PhD

Blood (2019) 134 (Supplement_1): 2534.

https://doi.org/10.1182/blood-2019-129157

Published: 2019

Journal Articles

Gilteritinib and Venetoclax Synergize to Eliminate FLT3/ITD+ Leukemia Cells through BIM

Ruiqi Zhu, PhD, Li Li, MD PhD, Bao Nguyen, MS, Amy S. Duffield, MD PhD, Donald Small, MD PhD

Blood (2019) 134 (Supplement_1): 2564.

https://doi.org/10.1182/blood-2019-131635

Published: 2019

Journal Articles

FLT3 Inhibitor Correlative Laboratory Assays Impact Outcomes in KMT2A-Rearranged Infant Acute Lymphoblastic Leukemia (ALL) Patients Treated with Lestaurtinib: AALL0631, a Children's Oncology Group Study

Patrick A. Brown, MD, John Kairalla, Joanne M. Hilden, MD, Zoann Eckert Dreyer, MD, Andrew J. Carroll, PhD, Nyla A. Heerema, PhD, Cindy Wang, MS, Meenakshi Devidas, PhD, William L. Carroll, MD, Elizabeth A. Raetz, MD, Mignon L. Loh, MD, Stephen P. Hunger, MD, Michael J. Borowitz, MD PhD, Donald Small, MD PhD

Blood (2019) 134 (Supplement_1): 1293.

https://doi.org/10.1182/blood-2019-130564

Published: 2019

Journal Articles

The Combination of PARP Inhibitors and DNMT Inhibitors Modulates Immune Activity and Suggests a Role for Immune Therapy in AML

Aksinija A Kogan, BS, MS, Michael Topper, BS, Susannah C Shissler, BS, Michael S Lee, BS, Dominique R Bollino, BS, Eun Yong Choi, Rena G Lapidus, PhD, Li Li, MD PhD, Donald Small, MD PhD, Maria R. Baer, MD, Tonya J Webb, PhD, Stephen Baylin, MD, Feyruz V. Rassool, BSc, PhD

Blood (2018) 132 (Supplement 1): 3886.

https://doi.org/10.1182/blood-2018-99-117294

Published: 2018

Journal Articles

Combinatorial Approaches to Overcome Plasma Protein Inhibition of FLT3 Tyrosine Kinase Inhibitors

David J Young, MD PhD, Jun O Liu, PhD, Donald Small, MD PhD

Blood (2018) 132 (Supplement 1): 1362.

https://doi.org/10.1182/blood-2018-99-118820

Published: 2018

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Pre-clinical efficacy of FLT3/BRAF targeting with novel dual inhibitor PHI3 in FLT3/RAS co-mutated AML

Spatial asymmetry of blasts in bone marrow after hematopoietic stem cell transplantation for AML/MDS

Sphingosine-1-phosphate receptor modulators overcome FLT3 inhibitor resistance in Acute Myeloid Leukemia with FLT3-ITD and NRAS mutations through sphingosine kinase 1/AKT pathway downregulation.

PHI-101, a Novel FLT3 TKI, Shows Clinical Efficacy in Relapsed/Refractory FLT3-Mutated AML

Evaluation of Synergistic Anti-Leukemic Efficacy of PHI-101 in Preclinical Model of FLT3-ITD Acute Myeloid Leukemia

Long Noncoding RNA NEAT1 Regulates Acute Graft-Versus-Host Disease By Promoting Macrophage M1 Polarization through JNK Pathway

PHI-101 As a Potent Next-Generation FLT3 Inhibitor, Overcome Resistances in Previously Treated Patients with FLT3-ITD or TKD Acute Myeloid Leukemia: Results of a Phase Ia/Ib Clinical Trial

SHP2 Inhibition Overcomes Adaptive and Acquired Resistance to FLT3 TKI to Improve Efficacy Against FLT3/ITD AML

Targeting SIRT5 By Succinylating Hadha Synergizes with Venetoclax in Acute Myeloid Leukemia

Inhibition of NOTCH4 Sensitizes FLT3/ITD Acute Myeloid Leukemia Cells to FLT3 Tyrosine Kinase Inhibition

Humanized Anti-CD25 Monoclonal Antibody Replacing MTX for Graft-Versus-Host Disease Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplantation

A Potent Small Molecule Inhibitor of FLT3, PHI-101 Overcomes Resistance in Acute Myeloid Leukemia: Efficacy and PK/PD Profile in Phase 1 First in Human Study

A Phase 1a/1b First in Human Study of PHI-101, a Potent Small Molecule Inhibitor of FLT3 in Relapsed and Refractory Acute Myeloid Leukemia

PHI-101 Is a Potent Third-Generation FLT3 Inhibitor Developed to Overcome Resistance in Acute Myeloid Leukemia

Dissociation of the DNMT3A-HDAC1 Repressor Complex Induces PD-L1 Expression

DOCK2 Expression Affects Leukemogenesis and Disease Progression in a Murine Model of FLT3/ITD Acute Myeloid Leukemia

Gilteritinib and Venetoclax Synergize to Eliminate FLT3/ITD+ Leukemia Cells through BIM

FLT3 Inhibitor Correlative Laboratory Assays Impact Outcomes in KMT2A-Rearranged Infant Acute Lymphoblastic Leukemia (ALL) Patients Treated with Lestaurtinib: AALL0631, a Children's Oncology Group Study

The Combination of PARP Inhibitors and DNMT Inhibitors Modulates Immune Activity and Suggests a Role for Immune Therapy in AML

Combinatorial Approaches to Overcome Plasma Protein Inhibition of FLT3 Tyrosine Kinase Inhibitors

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only